JAK1 and breast cancer: Indeed, in breast cancer, ATP stimulation on the P2Y2 receptor could induce chemoresistance towards a variety of chemotherapeutic agents, including cisplatin, doxorubicin, paclitaxel, and gemcitabine, via indirect activation of IL-6 to trigger its downstream JAK-1-SOX9 signaling [55].